Search - tctmd.com

Displaying 221 - 240 of 264

Sort: Relevancy | Date

Presentation TCTAP 2012

Results of RESOLUTE Series of Studies

Presenter: Martin B. Leon

April 26, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

Presentation ACC 2012

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Presenter: Laura Mauri

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Daily News

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

L.A. McKeown

February 20, 2012

Presentation

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Presenter: C. Von Birgelen

February 20, 2012

News Industry News

Medtronic Resolute Integrity™ Drug-Eluting Stent Obtains FDA Approval for Treating Coronary Artery Disease

February 19, 2012

News Daily News

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

January 24, 2012

News Daily News

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

Jason Kahn

January 08, 2012

News Daily News

SCAAR: Second-Generation DES Improve Hard Outcomes

Yael L. Maxwell

January 08, 2012

Presentation TCT 2012

Safety and Efficacy of the Resolute Zotarolimus-eluting Stent in Patients ? 70 Years of Age.

Presenter: Ganesh Manoharan, Alan C. Yeung, Petr Widimsky, Franz-Josef Neumann, Patrick W. Serruys, Sigmund Silber, Stephan Windecker, Martin B. Leon, Laura Mauri, Shigeru Saito, Ian T. Meredith, Jorge Belardi

January 03, 2012

Presentation TCT 2012

Relative Dose and Vascular Response After Resolute Zotarolimus-Eluting Stent Implantation: A Dosimetric 3D-Intravascular Ultrasound Study.

Presenter: Hideki Kitahara, Teruyoshi Kume, Katsuhisa Waseda, Kenji Sakamoto, Ryotaro Yamada, Paul Yock, Ian T. Meredith, Martin B. Leon, Laura Mauri, Alan C. Yeung, Peter J. Fitzgerald, Yasuhiro Honda

January 03, 2012

Presentation TCT 2012

Impact of Stent Size and Length on Neointimal Hyperplasia After Resolute Zotarolimus-Eluting Stent Implantation: Insights From RESOLUTE Trials

Presenter: Ryotaro Yamada, Teruyoshi Kume, Katsuhisa Waseda, Hideki Kitahara, Kenji Sakamoto, Paul G. Yock, Ian T. Meredith, Martin B. Leon, Laura Mauri, Aran C. Yeung, Yasuhiro Honda, Peter J. Fitzgerald

January 03, 2012

Presentation TCT 2012

Impact Of Stent Length In Diffuse Coronary Disease On Clinical Outcome After Zotarolimus-Resolute-Eluting Stent Implantation:an Italian Multicentre Observational Evaluation

Presenter: Claudio Larosa, Enrico Romagnoli, Azeem Latib, Giovanni Valenti, Gianluigi Minervini, Francesco Burzotta, Ernesto Lioy, Antonella Tommasino, Vincenzo Cucci, Maria De Vita, Piero Montorsi, Antonio Colombo

January 03, 2012

News Daily News

Some New-Generation Stents Prone to Longitudinal Distortion

November 29, 2011

News Conference News

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

L.A. McKeown

November 28, 2011

Advertisement

Results of RESOLUTE Series of Studies

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Resolute Integrity: New Zotarolimus-Eluting Stent Gains FDA Approval

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute vs. Everolimus-Eluting Xience V in Real-World Patients: TWENTE

Medtronic Resolute Integrity™ Drug-Eluting Stent Obtains FDA Approval for Treating Coronary Artery Disease

NEXT Up: Polymer-Free SES Angiographically Superior to Taxus

Stent Thrombosis, TLR Persist at Low Levels out to 5 Years with First-Gen DES

SCAAR: Second-Generation DES Improve Hard Outcomes

Safety and Efficacy of the Resolute Zotarolimus-eluting Stent in Patients ? 70 Years of Age.

Relative Dose and Vascular Response After Resolute Zotarolimus-Eluting Stent Implantation: A Dosimetric 3D-Intravascular Ultrasound Study.

Impact of Stent Size and Length on Neointimal Hyperplasia After Resolute Zotarolimus-Eluting Stent Implantation: Insights From RESOLUTE Trials

Impact Of Stent Length In Diffuse Coronary Disease On Clinical Outcome After Zotarolimus-Resolute-Eluting Stent Implantation:an Italian Multicentre Observational Evaluation

Some New-Generation Stents Prone to Longitudinal Distortion

TWENTE: Zotarolimus DES Noninferior to Everolimus DES at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content